Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial

Table 1 Baseline demographics of trial participants

	Group A (n = 12)^a Saline then liraglutide	Group B (n = 10)^a Liraglutide then saline
Mean age ± SD	65.3 ± 7.3	59.2 ± 9.1
Sex	11 male (91.7%)	9 male (90%)
Mean body mass index ± SD	30.1 ± 3.4	29.6 ± 4.8
Severity of CAD	1VD = 2/12 (16.7%) MVD = 10/12 (83.3%)	1VD = 0/12 (0%) MVD = 10/10 (100%)
Prior CVA/TIA	2/12 (16.7%)	1/10 (10%)
Prior MI	4/12 (33.3%)	2/10 (20%)
Prior PCI	2/12 (16.7%)	3/10 (30%)
Prior CABG	1/12 (8.3%)	0/10 (0%)
Hypertension	7/12 (58.3%)	6/10 (60%)
Type 2 diabetes mellitus	1/12 (8.3%)	0/10 (0%)
Hypercholesterolaemia	4/12 (33.3%)	6/10 (60%)
Smoker (past and present)	4/12 (33.3%)	10/10 (100%)
Family history of premature CAD	4/12 (33.3%)	2/10 (20%)

CABG coronary artery bypass graft, CAD coronary artery disease, CVA cerebrovascular accident, MI myocardial infarction, MVD multivessel disease, PCI percutaneous coronary intervention, SD standard deviation, TIA transient ischaemic attack
^aIndividuals acted as their own controls within the crossover nature of the study protocol. As such no inter-group comparisons have been made

ISSN: 1758-5996